Discovery and Characterization of the Tuberculosis Drug Lead Ecumicin

Organic Letters - United States
doi 10.1021/ol5026603
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets

Cold Spring Harbor perspectives in medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Lead the Way in GPCR Drug Discovery

Chemical and Engineering News
Chemical Engineering
2005English

Computational Chemistry in Drug Lead Discovery and Design

International Journal of Quantum Chemistry
Condensed Matter PhysicsMolecular Physics,Theoretical ChemistryAtomicOpticsPhysical
2018English

Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis

Frontiers in Microbiology
Microbiology
2018English

The Implications of Model-Informed Drug Discovery and Development for Tuberculosis

Drug Discovery Today
Drug DiscoveryPharmacology
2017English

New Approaches to Filling the Gap in Tuberculosis Drug Discovery

PLoS Medicine
BiochemistryBiotechnologyMolecular BiologyCell BiologyMedicine
2007English

The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active Against Mycobacterium Tuberculosis in Vivo

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2014English

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Characterization of Extensively Drug-Resistant Mycobacterium Tuberculosis in Nepal

Tuberculosis
Infectious DiseasesImmunologyMicrobiology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy